Profile of Premature Ovarian Failure in a Cohort of Hypofertile Couples at Bogodogo University Teaching Hospital, Ouagadougou, Burkina Faso

Abstract

Introduction: Premature ovarian insufficiency (POI) is not an uncommon phenomenon among patients who consulted during the assisted reproduction campaign. Objective: The aim of our study was to investigate the frequency and factors associated with premature ovarian failure (POI) in a cohort of women during the campaign for assisted reproduction at the University Teaching Hospital of Bogodogo (UTH-B) from December 15, 2022 to June 15, 2023. Methodology: We conducted a retrospective descriptive and analytical cross-sectional study from 2022 to 2023. The study population consisted of women with POI. Data were collected using a questionnaire containing the variables. We calculated frequency, crude odds ratios (crude OR) and adjusted odds ratios (adjusted OR) at a 95% confidence interval, and variables with a p-value < 0.05 were considered statistically significant. Results: The prevalence of premature ovarian failure was 4.42%. Factors independently associated with premature ovarian failure were irregularity of menstrual cycle [OR = 10.35, CI95% = (4.04-26.50), p = 0.001]; history of twins [OR = 3.55, CI95% = (1.63-7.69), p = 0.001]; absence of history of gestation [OR = 1.47, CI95% = (1.02-2.15), p = 0.047]. Conclusion: The study showed that POI remains a major challenge in reproductive health, due to its relatively high frequency. Action is needed to raise awareness of the signs, so that the population can be consulted at an early stage.

Share and Cite:

Adama, O. , Aminata, L. , Alexi, S. , Sibraogo, K. , Issa, O. and Charlemagne, O. (2025) Profile of Premature Ovarian Failure in a Cohort of Hypofertile Couples at Bogodogo University Teaching Hospital, Ouagadougou, Burkina Faso. Open Journal of Obstetrics and Gynecology, 15, 579-594. doi: 10.4236/ojog.2025.153047.

1. Introduction and Statement of the Problem

Atresia, which begins in intrauterine life, continues progressively, as do ovulations during puberty. Thus, premature menopause or premature ovarian insufficiency (POI) could occur in any woman who starts life with a decreased number of follicles or undergoes accelerated follicular apoptosis [1]. It is defined by the occurrence of primary or secondary amenorrhea lasting more than 4 months before the age of 40, associated with increased pituitary gonadotropins (FSH > 20 IU/L) and low estradiol levels on 2 occasions, at least 4 to 6 weeks apart are compatible with a diagnosis of POI [2] [3]. Demographic data have shown that around 3.7% of women worldwide suffer from POI and subsequent infertility [4]. This prevalence varied significantly by continent: in Latin America, it was 1.5%, and 1.9% in Europe [5]. However, it was higher in Asia and Africa, at 2.7% and 2.4% respectively [6] [7]. In Burkina Faso, a study conducted in 2023 found a prevalence of 2.4% [7].

In the same context as Burkina Faso, the level of infertility was estimated to be 17.76% of the general population in 2016 [8]. Tiemtoré found in his study that the causes were ovarian in 67.82% of cases, uterine in 25.28% and tubal in 6.89%. Moreover, the most frequent ovarian pathology was polycystic ovary syndrome (PCOS) (44.04%) [9]. For Sakande, tubal obstructions were the most common cause of hypofertility, accounting for 50.0% of cases [10].

The timing of menopause is an indicator of ovarian function and has important health implications. Indeed, premature ovarian failure is associated with an increased risk of all-cause mortality [11] [12]. To prevent the occurrence of these complications, it is necessary to be aware of the risk factors for premature ovarian failure. Worldwide, a number of studies have identified determinants of premature ovarian failure, including socioeconomic factors [12]-[14]. Furthermore, understanding and clarifying these risk factors will facilitate prevention strategies to optimize women’s health. We therefore set out to study the epidemiological profile, frequency and factors associated with premature ovarian failure in a cohort of hypofertile couples at the University Teaching Hospital Bogodogo (UTH-B), in order to contribute to better reproductive health in Burkina Faso.

2. Methodology

2.1. Setting and Field of Study

The University Teaching Hospital of Bogodogo (UTH-B) is located in the city of Ouagadougou, the political and administrative capital of Burkina Faso, which was our field of study and the CHUB, our study setting.

2.2. Type and Period of Study

This was a prospective descriptive and analytical cross-sectional study from December 15, 2022 to June 15, 2023.

2.3. Study Population

The study population consisted of all couples who participated in the campaign.

2.4. Selection Criteria

The patients included in our sample met the following criteria:

(1) Having under 40 years of age;

(2) Having participated in the screening campaign for medically assisted reproduction in the UTH-B obstetrics and reproductive medicine department;

(3) Having completed their biological work-up (FSH, LH, AMH, Oestradiol….);

(4) having carried out 2 previous biological assessments with an interval of at least 6 months and concordant;

(5) Having given their verbal consent over the telephone to participate in the study.

2.5. Collection Techniques and Tools

A literature review from August 1 to October 302 with a questionnaire and a telephone interview from November 1 to 15 were used to collect the data.

2.6. Study Variables

The following variables were collected on the data collection forms:

(1) Socio-demographic characteristics: age, profession, marital status, level of education, place of origin;

(2) Gynaeco-obstetrical, medical and surgical history;

(3) Eating and physical habits;

(4) Clinical examination: blood pressure, Body mass index (BMI);

(5) Results of paraclinical examinations: hormone assessment (FSH, LH, estradiol, AMH, TSH prolactin…), ultrasound, hysterosalpingography (HSG), diagnostic hysteroscopy.

The dependent variable or variable of interest was premature ovarian failure, a qualitative binary variable (Yes/No). The independent variables were socio-demographic and lifestyle variables, and clinical and paraclinical variables.

2.7. Data Processing

A data entry mask was created and the data collected was entered progressively on a computer using Epi info software version 7.2.2.6. The manually collected data were entered, processed and analyzed on a computer, using Word, Excel version 2016 and Epi info version 7.2.5.0.

Data analysis involved 3 levels:

(1) Descriptive analysis: involved calculating percentages for qualitative variables and measures of central tendency (mean, median) and dispersion (standard deviation, minimum, maximum) for quantitative variables.

(2) Univariate analysis: the Chi-square test was used to compare percentages; when the conditions for applying the test were not met, Fisher’s exact test was used. The Student’s t-test was used to compare means.

(3) Multivariate analysis using logistic regression.

(4) A p threshold of less than 0.05 was considered significant; the Odds ratio was used as a measure of association with a 95% confidence interval.

3. Results

3.1. Descriptive Study

1. Frequency

A total of 1,200 women of all ages took part in the assisted reproduction campaign at CHU-B. Of these, 53 women were diagnosed with premature ovarian failure, representing a frequency of 4.42%.

2. Socio-Demographic and Lifestyle Characteristics

A total of 261 women under 40 years of age were included. The mean age of women with ovarian insufficiency was 34.64 ± 3.97 years, with extremes ranging from 24 to 39 years. The level of education was high in 206 women from the general population, 41 of whom (19.90%) had been screened for POI. In the study population, 242 women were married, including 50 women screened for POI, i.e. 20.66%, and 66 consumed alcohol, including 17 screened for POI, i.e. 25.76% (Table 1).

Table 1. Distribution of women according to socio-demographic and lifestyle characteristics during the CHUB 2022-2023 MPA campaign.

Features

Total N = 261

POI N = 53

No POI N = 208

N

N (%)

N (%)

Age groups

[20 - 30]

65

08 (12.31)

57 (87.69)

[31 - 40 ]

196

45 (22.96)

151 (77.04)

Educational level

High

206

41 (19.90)

165 (80.10)

Low

55

12 (21.82)

43 (78.18)

Occupation

Housewife

25

04 (16.00)

21 (84.00)

Salaried

150

33 (22.00)

117 (78.00)

Informal

58

14 (24.14)

44 (75.86)

Student

24

01 (4.16)

23 (95.84)

Farmer

04

01 (25.00)

3 (75.00)

Marital status

Married

242

50 (20.66)

192 (79.34)

Cohabiting

19

03 (15.79)

16 (84.21)

Residence

Rural

38

09 (23.68)

29 (76.32)

Urban

223

44 (19.73)

179 (80.27)

Body mass index

Normal

187

38 (20.32)

149 (79.68)

Low weight

03

01 (33.33)

02 (66.67)

Obesity

71

14 (19.72)

57 (80.28)

Alcohol

Yes

66

17 (25.76)

49 (74.24)

No

195

36 (18.46)

159 (81.54)

Physical activity

Yes

42

07 (16.66)

35 (83.34)

No

219

46 (21.00)

173 (79.00)

Age

33.43 ± 3.97

34.64 ± 3.96

33.12 ± 3.92

3. Clinical (History and Symptoms) and Paraclinical Data

In our study population, 145 women had an irregular menstrual cycle, including 48 with premature ovarian failure (33.10%). One hundred and thirty-four (134) women had dysmenorrhea, 23 of whom (17.16%) had been diagnosed with POI. Hypofertility was primary in 165 women, of whom 33 (20%) were screened for POI. Endometriosis was present in 18 women from the general population, including 3 with premature ovarian failure (16.66%). Diabetes was present in 7 women from the general population, including 3 women (42.86%) with premature ovarian failure. IVF was performed in 20 women from the general population, including 9 with premature ovarian failure (45%). Myomectomy was performed on 26 women from the general population, including 6 (23.08%) with premature ovarian failure (Table 2).

Table 2. Distribution of women according to their history during the AMP campaign at CHU B.

Features

Total N = 261

N

POI N = 53

N (%)

No POI N = 208

(%)

Menstrual cycle irregularity

No

116

05 (4.31)

111 (95.69)

Yes

145

48 (33.10)

97 (66.90)

Dysmenorrhea

134

23 (17.16)

111 (82.84)

Yes

127

30 (23.62)

97 (76.38)

No

Spaniomenorrhea

54

11 (20.37)

43 (79.63)

Yes

207

42 (20.29)

165 (79.71)

No

Contraception

39

08 (20.51)

31 (79.49)

Yes

222

45 (20.27)

177 (79.73)

No

Hypofertility

165

33 (20.00)

132 (80.00)

Primary

96

20 (20.83)

76 (79.17)

Secondary

Previous pregnancy

96

23 (23.96)

73 (76.04)

Yes

165

30 (18.18)

135 (81.82)

No

Previous childbirth

39

10 (25.64)

29 (74.36)

Yes

222

43 (19.37)

179 (80.63)

No

Endometriosis

18

03 (16.66)

15 (83.34)

Yes

243

50 (20.58)

193 (79.42)

No

PCOS

14

02 (14.29)

12 (85.71)

Yes

247

51 (20.65)

196 (79.35)

No

hypertension

16

03 (18.75)

13 (81.25)

Yes

245

50 (20.41)

195 (79.59)

No

Diabetes

07

03 (42.86)

04 (57.14)

Yes

254

50 (19.69)

204 (80.31)

No

Salpingectomy

14

04 (28.57)

10 (71.43)

Yes

247

49 (19.84)

198 (80.16)

No

Salpingoplasty

13

01 (7.69)

12 (92.31)

Yes

248

52 (20.97)

196 (79.03)

No

Myomectomy

26

06 (23.08)

20 (76.92)

Yes

235

47 (20.00)

188 (80.00)

No

Drilling

06

00 (0.00)

06 (100.0)

Yes

255

53 (20.78)

202 (79.22)

No

Cystectomy

13

04 (30.77)

09 (69.23)

Yes

248

49 (19.76)

199 (80.24)

No

Ovariectomy

03

02 (66.67)

01 (33.33)

Yes

258

51 (19.77)

207 (80.23)

No

Caesarean section

07

01 (14.29)

06 (85.71)

Yes

254

52 (20.47)

202 (79.53)

No

Stimulation

67

18 (26.87)

49 (73.13)

Yes

194

35 (18.04)

159 (81.96)

No

Insemination

22

04 (18.18)

18 (81.82)

Yes

239

49 (20.50)

190 (79.50)

No

IVF

20

09 (45.00)

11 (55.00)

Yes

241

44 (18.26)

197 (81.74)

No

Family history of POI

00

00 (0.00)

00 (0.00)

Yes

261

53 (20.30)

208 (79.70)

No

History of twins

18

12 (66.67)

06 (33.33)

Yes

243

41 (16.87)

202 (83.13)

No

7.1 ± 3.77

6.7 ± 3.32

7.18 ± 3.90

Duration of hypofertility in years

13.95 ± 1.61

14.03 ± 1.60

13.93 ± 1.61

Dyspareunia was present in 55 women, including 53 with premature ovarian failure (96.36%). AMH levels were low in 177 women from the general population and in all women with PCOI (Table 3).

Table 3. Distribution of women according to symptoms and biological result during the PMA campaign at CHU B 2022-2023.

Features

Total N = 261

N

POI N = 53

N (%)

No POI

N (%)

Amenorrhea

Yes

70

25 (35.71)

45 (64.29)

No

191

28 (14.66)

163 (85.34)

Hot flushes

Yes

47

39 (82.98)

08 (17.02)

No

214

14 (6.54)

200 (93.46)

Loss of attention and memory

Yes

34

34 (100.0)

00 (0.00)

No

227

19 (8.37)

208 (91.63)

Vaginal dryness

Yes

55

53 (96.36)

02 (3.64)

No

206

00 (0.00)

206 (100.0)

Dyspareunia

Yes

55

53 (96.36)

02 (3.64%)

²No

206

00 (0.00)

206 (100.0)

Sleep disturbance

Yes

45

12 (26.66)

33 (73.34)

No

216

41 (18.98)

175 (81.02)

AMH

Normal

84

00 (0.00)

84 (100.0)

Low

177

53 (29.94)

124 (70.06)

3.2. Etiological Analysis

1. Univariate Analysis

In our study, the variables associated with premature ovarian failure in univariate analysis (Table 4) were: history of gemellity (p = 0.002); history of pregnancy (p = 0.049); irregularity of menstrual cycle (p = 0.000), age over 30 (p = 0.068), diabetes (p = 0.018), oophorectomy (p = 0.089).

Table 4. Factors associated with premature ovarian failure in women during the CHUB 2022-2023 MAP campaign in univariate analysis.

Variables

OR

IC 95%

P

PCOS

No

1

Yes

2.56

[1.38, 4.74]

0.002

Previous

childbirth

1

No

1.80

[0.53, 6.11]

0.340

Yes

Salpingectomy

1

No

1.2

[0.45, 3.15]

0.711

Yes

Insemination

1

No

0.64

[0.13, 2.95]

0.568

Yes

Dysmenorrhea

1

No

0.69

[0.31, 1.53]

0.370

Yes

Alcohol

1

No

1.61

[0.48, 5.37]

0.432

Yes

Contraception

1

No

0.86

[0.27, 2.66]

0.795

Yes

Marital status

1

Married

1.30

[0.71, 2.39]

0.391

Cohabiting

Single

1

High blood pressure

1.53

[1.79, 2.96]

0.104

No

Yes

1

Hypofertility

0.98

[0.42, 2.28]

0.972

No

Yes

1

Physical activity

0.70

[0.19, 2.54]

0.588

No

0.91

[0.47, 1.78]

0.804

Yes

Diabetes

1

No

0.90

[0.24, 3.28]

0.873

Yes

Caesarean section

1

No

1.05

[0.56, 1.96]

0.871

Yes

Residence

1

Rural

1.32

[0.55, 3.18]

0.523

Urban

Ovariectomy

1

No

10.90

[1.49, 79.90]

0.018

Yes

Pregnancy history

1

Yes

0.64

[0.07, 5.49]

0.690

No

Endometriosis

1

No

0.79

[0.34, 1.79]

0.576

Yes

Cycle irregularity

1

No

8.11

[0.72, 91.28]

0.089

Yes

Salpingoplasty

1

No

1.36

[1.02, 1.87]

0.049

Yes

Level of education

1

High

1.05

[0.52, 2.11]

0.887

Low

Profession

1

Housewife

9.32

[3.82, 22.74]

0.000

Salaried

Informal

1

Student/Grower

0.31

[0.04, 2.47]

0.271

BMI

1

0.873

Normalrange

0.84

[0.39, 1.80]

0.659

Overweight

1

Obese

1.48

[0.47, 4.61]

0.498

Age range >30 years

1.67

[0.48, 5.69]

0.412

No

0.22

[0.02, 2.20]

0.202

Yes

1.75

[0.14, 21.38]

0.661

PCOS

No

1

Yes

0.01

[0.001, 100.02]

0.976

Previous

1.30

[0.13, 12.8]

0.819

childbirth

No

1

Yes

2.12

[1.94, 4.77]

0.068

2. Multivariate Analysis

After uni-variate analysis, variables with p-values less than or equal to 0.20 were retained for multivariate analysis, and those with p-values less than 0.05 were significant.

Factors associated with POI were: cycle irregularity (p = 0.001); previous twin (p = 0.001); previous pregnancy (p = 0.047).

Table 5. Factors associated with premature ovarian failure in women during the campaign for assisted reproduction at CHUB 2022-2023 in multivariate analysis.

Variables

OR

IC 95%

P

Cycle irregularity

No

1

Yes

10.35

[4.04, 26.50]

0.001

Ovariectomy

No

1

Yes

5.12

[0.36, 72.22]

0.225

Pregnancy history

No

1

Yes

3.55

[1.63, 7.69]

0.001

Age range >30 years

No

1

Yes

0.67

[0.20, 2.21]

0.517

Pregnancy history

Yes

1

No

1.47

[1.02, 2.15]

0.047

Alcohol

No

1

Yes

4.91

[0.94, 25.60]

0.068

Diabetes

No

1

Yes

4.31

[0.44, 41.80]

0.207

4. Discussion

In our study, the frequency of premature ovarian failure was 4.42%, and the factors associated with premature ovarian failure on multivariate analysis were: cycle irregularity (p = 0.001); previous twinhood (p = 0.001); previous pregnancy (p = 0.047).

4.1. Limitations and Difficulties of the Study

Our study had certain limitations and biases, notably the retrospective nature of the study, where some data were incomplete and some patients were unreachable, and the small sample size. In addition, the study was carried out in Ouagadougou, the capital of Burkina Faso, which may reduce the participation of women living in rural areas, thus compromising the extrapolation of results to the entire population of Burkina Faso. Notwithstanding these limitations and biases, we were able to compare our results with the literature.

4.2. Frequency

The frequency of premature ovarian failure in our study was 4.4%. Our prevalence is higher than that of Coulibaly et al. (2.4%), Yeo J H et al. (3.1%), Mishra G D et al. (2%), Jambarsang S et al. (3%), Rostami Dovom M (3.5%), Lim J M (2.4%) [12] [15]-[18]. This discrepancy could be explained by the small size of our sample and our reduced study period; the prevalence of POI would have been overestimated.

4.3. Social and Demographic Characteristics

1. Age

The mean age of our patients with premature ovarian failure was 34.64 years. Our results are similar to those of Coulibaly et al., Sato et al. and Zhu D, who found a mean age of 32.8, 32.9 and 33.52 years respectively [7] [19]-[21]. This average age could be explained in our context by late consultations due to financial or cultural constraints (traditional treatment).

2. Level of Education

In our study, the highest level of education was represented by 41 of the 53 women with POI. This is explained by the fact that the campaign took place in Ouagadougou, where the majority of vocational schools and universities were located. Also, the campaign was well publicized, and women with a high level of education had easy access to information. This is confirmed by certain studies which show that women with a high level of education are generally more aware of the symptoms, which may influence the earliness of diagnosis [4] [22].

4.4. Clinical Characteristics

1. Duration and Type of Hypofertility

The average duration of hypofertility was 6.70 years. Our duration is shorter than that of Coulibaly et al. and longer than that of Zhu D et al. who reported a mean duration of 8.5 and 3.47 years respectively [7] [21]. Hypofertility was primary in 62.26% of our patients. Our rate is lower than that of Coulibaly et al. which was 72.55%, and higher than that of Zhu D et al. which was 32.25% [21].

Our results are based on patients with premature ovarian failure and Coulibaly’s [7]. On the general population, hence the difference. The difference between our results and those of Zhu is explained by the delay in consultation due to financial difficulties and the fact that the problem of fertility remains a taboo subject in our context. In addition, the fact that our patients were recruited in the context of a fertility campaign where the cost of procedures was lower than in private structures could justify this. Could this difference also be an expression of renewed hope for couples with a long history of infertility?

2. Duration of Menarche

The average age of menarche in our study was 14.03 ± 1.60 years, higher than that of Bompoula et al. who reported an average age of 12.2 ± 2.2 [23]. This difference may be explained by nutritional conditions and climate, which can influence pubertal development through hormonal and metabolic mechanisms.

3. Dyspareunia and Hot Flushes

In our study, dyspareunia and hot flushes were major symptoms in 96.30% of cases. Our results corroborate those of Sullivan et al., Gupta et al., Moustaki M. et al., who found these two symptoms to be among the signs presented by women screened for POI [4] [22] [24] [25]. These signs are part of the classic signs of menopause linked to estrogen deficiency. Estrogen deficiency leads to vulvovaginal atrophy through reduced vascularization and thickness of the vaginal epithelium. This deficiency can also lead to dysregulation of the hypothalamus, causing instability of the thermal regulation threshold, leading to sudden vasodilatation and increased sweating. These symptoms underline the importance of hormone replacement therapy for patients with POI [27].

4.5. Factors Associated with Premature Ovarian Failure

1. Menstrual Cycle Irregularity

In our study having an irregular mentstrual cycle increased the risk of having premature ovarian failure 10.35-fold and this was statistically significant with p value = 0.001. Our results corroborate those of Bertone-Johnson E R et al. in 2018 who reported that cycle irregularity increased the risk of having POI 6.3-fold and this was statistically significant with p < 0.001. Similarly, Whitcomb B W et al in 2018 found that women with regular cycles had a lower risk than women with irregular cycles (OR = 0.51; p-value = 0.0001) [26] [27]. Indeed, irregular menstrual cycles, often associated with periods of amenorrhea (absence of menses), may indicate impaired ovarian function. In addition, irregularity may be a sign of fluctuations in the production of hormones, particularly estrogen and progesterone, which are necessary for the proper functioning of cycles. This may reflect a reduced ovarian reserve or ovarian dysfunction. It is, therefore important to monitor irregular menstrual cycles and consult a doctor for assessment, especially if symptoms occur.

2. Twin Pregnancy History

Twin pregnancy increases the risk of premature ovarian failure and this is statistically significant with an OR = 3.55; p-value = 0.0013 Mishra G D et al. in 2019 reported that twin pregnancy history was associated with the risk of developing POI [12]. One of the main reasons that may link the outcome of a twin pregnancy to the accumulated risk of POI is genetic predisposition. Women with a genetic predisposition to hyperovulation (releasing multiple oocytes) may have a lower long-term ovarian reserve. In fact, multiple ovulation consumes oocytes more rapidly, which could accelerate the depletion of ovarian reserve and therefore increase the risk of premature ovarian failure (POF). If this tendency is passed on genetically to the daughter, she could also develop a reduced ovarian reserve earlier than average.

3. Previous Pregnancy

The absence of previous pregnancy is associated with a statistically significant risk of premature ovarian failure, with OR = 1.4732; p-value = 0.047.

In the literature, some authors have found that nulliparity is statistically associated with a risk of premature ovarian failure [14] [27]. This may be linked to the protective effects of hormones produced during pregnancy on ovarian function. These hormones may delay follicular exhaustion or limit oxidative damage to the ovaries.

The results of our study may be explained by the fact that POI leads to infertility, reducing the chances of pregnancy. Primary hypofertility (which accounts for 62.26% of our patients screened for POI) could mean that POI leads to pregnancy failure, rather than the reverse. Lack of pregnancy could also be linked to delays in diagnosis or limited access to care.

5. Conclusion

Premature ovarian failure represents a major reproductive health challenge due to its clinical and psychosocial implications. This study revealed a significant frequency of POI in the study population, as well as associated factors such as irregularity of the menstrual cycle, previous twinhood and previous pregnancy. These results underline the importance of early diagnosis and multidisciplinary management to improve the prognosis and quality of life of the patients concerned. They also call for increased awareness and targeted prevention strategies. Further research is needed to deepen understanding of the underlying mechanisms and develop innovative therapeutic approaches.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] ReGe, G., FoidaRt, J.M. and Nisolle, M. (2012) Prematured Ovarian Insufficiency. Revue Médicale de Liège, 7, 413-419.
[2] Torrealday, S., Kodaman, P. and Pal, L. (2017) Premature Ovarian Insufficiency—An Update on Recent Advances in Understanding and Management. F1000Research, 6, Article 2069.
https://doi.org/10.12688/f1000research.11948.1
[3] Torrealday, S. and Pal, L. (2015) Premature Menopause. Endocrinology and Metabolism Clinics of North America, 44, 543-557.
https://doi.org/10.1016/j.ecl.2015.05.004
[4] Moustaki, M., Kontogeorgi, A., Tsangkalova, G., Tzoupis, H., Makrigiannakis, A., Vryonidou, A., et al. (2023) Biological Therapies for Premature Ovarian Insufficiency: What Is the Evidence? Frontiers in Reproductive Health, 5, Article 1194575.
https://doi.org/10.3389/frph.2023.1194575
[5] Lagergren, K., Hammar, M., Nedstrand, E., Bladh, M. and Sydsjö, G. (2018) The Prevalence of Primary Ovarian Insufficiency in Sweden; a National Register Study. BMC Womens Health, 18, Article No. 175.
https://doi.org/10.1186/s12905-018-0665-2
[6] Leone, T., Brown, L. and Gemmill, A. (2023) Secular Trends in Premature and Early Menopause in Low-Income and Middle-Income Countries. BMJ Global Health, 8, e012312.
https://doi.org/10.1136/bmjgh-2023-012312
[7] Coulibaly, I. (2023) MPA Management of Premature Ovarian Failure in a Private Health Facility in the City of Ouagadougou in Burkina Faso from January 2021 to December 2022. Gynecology and Obstetrics, Université Joseph Ki Zerbo.
[8] Ministry of Health Burkina Faso (2018) Statistical Yearbook 2016 and 2017. 303.
[9] Kafando, J.G. (2020) Artificial Inseminations for Infertile Couples at the St Jérémie Clinic: Indications and Results from January 1, 2010 to December 31, 2019. Thesis Diploma of Specialized Studies in Gynecology Obstetrics, Joseph Ki Zerbo University —Training and Research Unit in Health Sciences.
[10] Sakande, J., Sandjon, L., Ouedraogo, C., Konyaole, E., Kabre, E. and Sawadogo, M. (2012) Profil hormonal féminin et pronostic de la réponse à la stimulation ovarienne au cours de l’Assistance Médicale à la Procréation: Expérience du Burkina Faso. International Journal of Biological and Chemical Sciences, 6, 950-958.
https://doi.org/10.4314/ijbcs.v6i3.4
[11] Mukandila, A.M., Sangula, M.K., Katumba, M.M., Kitengie, N., Tshiyamba, J.T., Kasongo, K., et al. (2020) Prevalence, Some Inherent Factors and Experience of Menopause in a Semi-Urban Environment (Case of the Town of Mwene-Ditu), Eastern Kasaia in the Democratic Republic of Congo. Revue Médicale des Grands Lacs, 11, 29.
[12] Mishra, G.D., Chung, H., Cano, A., Chedraui, P., Goulis, D.G., Lopes, P., et al. (2019) EMAS Position Statement: Predictors of Premature and Early Natural Menopause. Maturitas, 123, 82-88.
https://doi.org/10.1016/j.maturitas.2019.03.008
[13] Yasui, T., Hayashi, K., Mizunuma, H., Kubota, T., Aso, T., Matsumura, Y., et al. (2012) Factors Associated with Premature Ovarian Failure, Early Menopause and Earlier Onset of Menopause in Japanese Women. Maturitas, 72, 249-255.
https://doi.org/10.1016/j.maturitas.2012.04.002
[14] Mishra, G.D., Pandeya, N., Dobson, A.J., Chung, H., Anderson, D., Kuh, D., et al. (2017) Early Menarche, Nulliparity and the Risk for Premature and Early Natural Menopause. Human Reproduction, 32, 679-686.
https://doi.org/10.1093/humrep/dew350
[15] Yeo, J.H. and Kim, M.T. (2022) Association of Weight, Smoking, and Alcohol Consumption with Age at Natural Menopause. Journal of Women & Aging, 35, 343-353.
https://doi.org/10.1080/08952841.2022.2050157
[16] Jambarsang, S., Khodayarian, M., Sefidkar, R. and Yoshany, N. (2023) Prevalence of Premature Ovarian Insufficiency (POI) and Its Relationship with Female Reproductive Factors in Iranian Women: A Cross-Sectional Study from the Persian (shahedieh) Cohort Data. BMC Womens Health, 23, Article No. 467.
https://doi.org/10.1186/s12905-023-02620-9
[17] Rostami Dovom, M., Bidhendi-Yarandi, R., Mohammad, K., Farahmand, M., Azizi, F. and Ramezani Tehrani, F. (2021) Prevalence of Premature Ovarian Insufficiency and Its Determinants in Iranian Populations: Tehran Lipid and Glucose Study. BMC Womens Health, 21, Article No. 79.
https://doi.org/10.1186/s12905-021-01228-1
[18] Lim, Y., Jeong, K., Lee, S.R., Chung, H.W. and Lee, W. (2019) Association between Premature Ovarian Insufficiency, Early Menopause, Socioeconomic Status in a Nationally Representative Sample from Korea. Maturitas, 121, 22-27.
https://doi.org/10.1016/j.maturitas.2018.12.004
[19] Bustami, M., Matalka, K.Z., Elyyan, Y., Hussein, N., Hussein, N., Abu Safieh, N., et al. (2021) Age of Natural Menopause among Jordanian Women and Factors Related to Premature and Early Menopause. Risk Management and Healthcare Policy, 14, 199-207.
https://doi.org/10.2147/rmhp.s289851
[20] Sato, T., Kusuhara, A., Kasahara, Y., Haino, T., Kishi, H. and Okamoto, A. (2021) Follicular Development during Hormone Replacement Therapy in Patients with Premature Ovarian Insufficiency. Reproductive Medicine and Biology, 20, 234-240.
https://doi.org/10.1002/rmb2.12375
[21] Zhu, D.S., Chung, H.-F., Pandeya, N., Dobson, A.J., Cade, J.E., Greenwood, D.C., et al. (2018) Relationships between Intensity, Duration, Cumulative Dose, and Timing of Smoking with Age at Menopause: A Pooled Analysis of Individual Data from 17 Observational Studies. PLOS Medicine, 15, e1002704.
https://doi.org/10.1371/journal.pmed.1002704
[22] Gupta, A., Tiwari, P. and Khare, C. (2019) Premature Ovarian Insufficiency: A Review.
https://www.emjreviews.com/reproductive-health/article/premature-ovarian-insufficiency-a-review/
[23] Bompoula, M.S., Valsamakis, G., Neofytou, S., Messaropoulos, P., Salakos, N., Mastorakos, G., et al. (2020) Demographic, Clinical and Hormonal Characteristics of Patients with Premature Ovarian Insufficiency and Those of Early Menopause: Data from Two Tertiary Premature Ovarian Insufficiency Centers in Greece. Gynecological Endocrinology, 36, 693-697.
https://doi.org/10.1080/09513590.2020.1739266
[24] Sullivan, S.D., Sarrel, P.M. and Nelson, L.M. (2016) Hormone Replacement Therapy in Young Women with Primary Ovarian Insufficiency and Early Menopause. Fertility and Sterility, 106, 1588-1599.
https://doi.org/10.1016/j.fertnstert.2016.09.046
[25] Bertone-Johnson, E.R., Manson, J.E., Purdue-Smithe, A.C., Steiner, A.Z., Eliassen, A.H., Hankinson, S.E., et al. (2018) Anti-Müllerian Hormone Levels and Incidence of Early Natural Menopause in a Prospective Study. Human Reproduction, 33, 1175-1182.
https://doi.org/10.1093/humrep/dey077
[26] Whitcomb, B.W., Purdue-Smithe, A., Hankinson, S.E., Manson, J.E., Rosner, B.A. and Bertone-Johnson, E.R. (2018) Menstrual Cycle Characteristics in Adolescence and Early Adulthood Are Associated with Risk of Early Natural Menopause. The Journal of Clinical Endocrinology & Metabolism, 103, 3909-3918.
https://doi.org/10.1210/jc.2018-01110
[27] Lambrinoudaki, I., Paschou, S.A., Lumsden, M.A., Faubion, S., Makrakis, E., Kalantaridou, S., et al. (2021) Premature Ovarian Insufficiency: A Toolkit for the Primary Care Physician. Maturitas, 147, 53-63.
https://doi.org/10.1016/j.maturitas.2020.11.004

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.